The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.

A comprehensive development agenda on tenofovir alafenamide in clinical practice / Di Biagio, A; Riccardi, N; Rusconi, S; Guaraldi, G; Borderi, M; De Luca, A; Gianotti, N; Lo Caputo, S; Maggi, P; Maserati, R; Maggiolo, F. - In: AIDS REVIEWS. - ISSN 1139-6121. - 20:2(2018), pp. 75-82. [10.24875/AIDSRev.M18000017]

A comprehensive development agenda on tenofovir alafenamide in clinical practice

Guaraldi G;
2018-01-01

Abstract

The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.
20
2
75
82
A comprehensive development agenda on tenofovir alafenamide in clinical practice / Di Biagio, A; Riccardi, N; Rusconi, S; Guaraldi, G; Borderi, M; De Luca, A; Gianotti, N; Lo Caputo, S; Maggi, P; Maserati, R; Maggiolo, F. - In: AIDS REVIEWS. - ISSN 1139-6121. - 20:2(2018), pp. 75-82. [10.24875/AIDSRev.M18000017]
Di Biagio, A; Riccardi, N; Rusconi, S; Guaraldi, G; Borderi, M; De Luca, A; Gianotti, N; Lo Caputo, S; Maggi, P; Maserati, R; Maggiolo, F
File in questo prodotto:
File Dimensione Formato  
aids_2018_20_2_075-082.pdf

non disponibili

Tipologia: Versione pubblicata dall'editore
Dimensione 174.27 kB
Formato Adobe PDF
174.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1166676
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact